Search results for: Precision Medicine
Filter search results
R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
1 July 2018
…top-5 European countries and; (iii) although in-class competition is a necessary condition for early adoption and fast uptake of innovative medicines, it is not sufficient as there are other factors…
Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C
26 July 2018
…data exclusivity (DE), and Supplementary Protection Certificates (SPCs), is seen as important. This is due to the high cost of research and development (R&D) for new medicines and the issue…
H.R. 3 is the Wrong Policy for the Wrong Problem
10 September 2021
…the latest innovative medicines and technologies. Nearly 90% of all newly launched medicines are available in the US while only about half are available in other countries such as Canada…
Around The World in HTAs: Spain – Are We There Yet?
15 March 2023
…(CISNS), which makes the final decisions that are then formally adopted and implemented by the MoH. Assessment of medicines After the European Medicines Agency marketing authorisation or approval, a government…
Women in Medicine: The Results of an Inquiry Conducted by the Medical Practitioners’ Union in 1962 – 63
1 July 1966
Share this: Download publication Patricia M. Elliott The results of an inquiry conducted by the Medical Practitioners’ Union in 1962-63. Share this: Download publication…
NICE’s new cost-effectiveness threshold: Significance, consequences, and unanswered questions
25 February 2026
…£25,000-£35,000 per QALY will result in three to five more medicines recommended each year. At the heart of the matter is a structural challenge: NICE guides decisions about which medicines…
Medicine and Society: the Changing Demands for Medical Care
1 October 1972
The control of the major health problems of the early part of the twentieth century represents a triumph for medical progress in the past twenty-five years. Developments in pharmacology and…
Innovation in Medicines: Can We Value Progress?
1 August 2010
Summarised in this publication are the main points and conclusions from a discussion facilitated by OHE that focused on innovation in the pharmaceutical industry. Participants included representatives of the pharmaceutical…
European Medicines Pricing and Reimbursement: Now and the Future
1 January 2007
Available from Radcliffe publishing: https://www.radcliffe-oxford.com/books/bookdetail.aspx?ISBN=184619184X Published in association with the Office of Health Economics this book is a vital, non-technical guide illuminating recent developments within the five major European pharmaceutical…